keyword
MENU ▼
Read by QxMD icon Read
search

BPH medication

keyword
https://www.readbyqxmd.com/read/28730999/surgery-for-benign-prostatic-hyperplasia-profile-of-patients-in-a-tertiary-care-institution
#1
Rahul Rajeev, Bhuwan Giri, Lok Prakash Choudhary, Rajeev Kumar
BACKGROUND: Medical therapy is widely used for managing benign prostatic hyperplasia (BPH) and has made an impact on the profile of patients who ultimately undergo surgery. This changing profile may impact outcomes of surgery and associated complications. To assess the impact of medical management, we evaluated the profile of patients who had surgery for BPH at our institution. METHODS: A retrospective chart-review was performed of patient demographics, indications for surgery, preoperative comorbid conditions and postoperative course in patients who underwent surgery for BPH over a 5-year period...
January 2017: National Medical Journal of India
https://www.readbyqxmd.com/read/28721281/safety-and-efficacy-of-tamsulosin-alfuzosin-or-silodosin-as-monotherapy-for-luts-in-bph-a-double-blind-randomized-trial
#2
Chikka Moga Siddaiah Manohar, Mahadevappa Nagabhushana, Vilvapathy Senguttuvan Karthikeyan, Ramachandra Pudakalkatti Sanjay, Ananth Janardhan Kamath, Ramaiah Keshavamurthy
INTRODUCTION: Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH. MATERIAL AND METHODS: Consecutive consenting male patients (N = 269) undergoing medical management of BPH with AB from February 2012 to October 2015 were enrolled. Patients were randomized to a 0...
June 30, 2017: Central European Journal of Urology
https://www.readbyqxmd.com/read/28665456/is-early-benign-prostatic-hyperplasia-bph-treatment-worthwhile
#3
Fabrizio Presicce, Cosimo De Nunzio, Andrea Tubaro
BACKGROUND: The medical armamentaria for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) have been extensively implemented over the past decade. Nevertheless, the timeliest moment for a possible treatment has not been fully established. EVIDENCE ACQUISITION: A systematic literature search in January 1996 until June 2016 was performed to answer the following question: in men with LUTS due to BPH, does early treatment result in better outcome? An ad hoc Population/patient Intervention/indicator Comparator/control Outcome (PICO) was developed...
June 19, 2017: Urologia
https://www.readbyqxmd.com/read/28646943/state-of-the-art-advanced-techniques-for-prostatic-urethral-lift-for-the-relief-of-prostate-obstruction-under-local-anesthesia
#4
Lance Patrick Walsh
Benign prostatic hypertrophy (BPH) affects an estimated 60% of men over the age of 50 and 90% of men over the age of 80. The prostatic urethral lift (PUL) is a safe and effective office-based procedure that is used worldwide for the treatment of BPH in men who are dissatisfied with medications due to side effects or lack of efficacy or don't want to have a transurethral resection of the prostate due to the side effects and invasiveness of the procedure. In 2012 Barkin et al, published the standard technique for the delivery of the Urolift implant...
June 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/28631916/-intravesical-prostatic-protrusion-in-diagnosing-infravesical-obstruction-in-men-with-benign-prostatic-hyperplasia
#5
G G Krivoborodov, N S Efremov, A D Bolotov
Infravesical obstruction (IVO) is an important characteristic of the functional state of male lower urinary tract. It is believed that IVO confirmed by pressure-flow study findings warrants switching from a medical to surgical management of lower urinary tract symptoms (LUTS). Intravesical prostatic protrusion (IPP) is a new indicator for detecting IVO secondary to benign prostatic hyperplasia (BPH). This indicator has several advantages over other non-invasive methods for evaluating IVO. The initial findings on the relationship between IPP and IVO suggest the feasibility of its clinical use as a screening tool in men with obstructive voiding symptoms...
June 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28631905/-rationale-of-pharmacotherapy-duration-in-patients-with-benign-prostatic-hyperplasia-a-clinical-morphological-study
#6
M E Sitdykova, D E Tsyplakov, E N Sitdykov, A R Nurtdinov
AIM: To investigate the nature of morphological alterations in the urinary bladder wall in BPH patients receiving pharmacotherapy to establish treatment time limits. MATERIALS AND METHODS: The study comprised 120 BPH patients who underwent a transvesical adenomectomy. Prior to the surgery, 110 patients received pharmacotherapy (-blockers and 5-reductase inhibitors) lasting from 1-6 months to 5-10 years. Preoperative evaluation included a standard diagnostic algorithm...
June 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28631904/-analysis-of-factors-affecting-the-compliance-with-medical-therapy-for-benign-prostatic-hyperplasia
#7
V A Malkhasyan, P I Rasner, A R Gevorkyan, I V Semenyakin, A V Tedeev, D Yu Pushkar
AIM: To investigate factors affecting the compliance of patients with the combination therapy for benign prostatic hyperplasia. MATERIALS AND METHODS: Four hundred BPH outpatients treated with combination therapy were surveyed. RESULTS: The absolute majority of patients (76.16%) expected a quick positive result. 10.47% viewed their disease as too advanced, did not believe in the effectiveness of medical therapy and believed the surgery to be the only treatment option...
June 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28593165/minimally-invasive-surgical-therapies-for-benign-prostatic-hypertrophy-the-rise-in-minimally-invasive-surgical-therapies
#8
REVIEW
Daniel Christidis, Shannon McGrath, Marlon Perera, Todd Manning, Damien Bolton, Nathan Lawrentschuk
The prevalence of benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms increases with our ageing population. Treatment of BPH traditionally begins with medical therapy and surgical intervention is then considered for those whose symptoms progress despite treatment. Minimally invasive surgical therapies have been developed as an intermediary in the treatment of BPH with the aim of decreasing the invasiveness of interventions. These therapies also aim to reduce morbidity and dysfunction related to invasive surgical procedures...
June 2017: Prostate International
https://www.readbyqxmd.com/read/28580382/differences-in-the-treatment-of-benign-prostatic-hyperplasia-comparing-the-primary-care-physician-and-the-urologist
#9
Adam J Rensing, Adrienne Kuxhausen, Joel Vetter, Seth A Strope
INTRODUCTION: Benign prostatic hyperplasia is a prevalent chronic condition with expenditures exceeding $1 billion each year. Little is known about management of patients by primary care physicians compared to urologists. We assessed changes in management after medication initiation in these two settings. METHODS: From the Chronic Condition Warehouse 5% sample of Medicare beneficiaries linked to Medicare Part D data, we defined a cohort of men, 66 to 90 years old, with initial prescriptions for alpha-blocker, 5-alpha reductase inhibitor (5-ARI), or both...
May 2017: Urology Practice
https://www.readbyqxmd.com/read/28540994/clinical-efficacy-and-safety-of-naftopidil-treatment-for-patients-with-benign-prostatic-hyperplasia-and-hypertension-a-prospective-open-label-study
#10
Mun Su Chung, Byung Il Yoon, Seung Hwan Lee
PURPOSE: To investigate the efficacy and safety of naftopidil for benign prostatic hyperplasia (BPH) patients, mainly focusing on changes in blood pressure (BP). MATERIALS AND METHODS: Of a total of 118 patients, 90 normotensive (NT) and 28 hypertensive (HT) patients were randomly assigned to be treated with naftopidil 50 mg or 75 mg for 12 weeks, once-daily. Safety and efficacy were assessed by analyzing changes from baseline in systolic/diastolic BP and total International Prostate Symptom Score (IPSS) at 4 and 12 weeks...
July 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28540239/the-impact-and-management-of-sexual-dysfunction-secondary-to-pharmacological-therapy-of-benign-prostatic-hyperplasia
#11
REVIEW
Jason Gandhi, Steven J Weissbart, Noel L Smith, Steven A Kaplan, Gautam Dagur, Anna Zumbo, Gargi Joshi, Sardar Ali Khan
Benign prostatic hyperplasia (BPH) is one of the most common genitourinary complications in men over 50 years of age and typically presents with lower urinary tract symptoms (LUTS). Classes of medications include α1-adrenoceptor blockers, 5α-reductase inhibitors, and phosphodiesterase 5 inhibitors. Today, α1-adrenoceptor blockers and 5α-reductase inhibitors are often combined to give a synergistic effect. A review of the current literature identified several adverse sexual side effects, including erectile dysfunction (ED), decreased libido, orgasmic disorders, and ejaculatory disorders...
April 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28506862/a-relevant-midterm-12-months-placebo-effect-on-lower-urinary-tract-symptoms-and-maximum-flow-rate-in-male-lower-urinary-tract-symptom-and-benign-prostatic-hyperplasia-a-meta-analysis
#12
Klaus Eredics, Stephan Madersbacher, Ingrid Schauer
OBJECTIVE: To assess the mid- to long-term placebo effect of the medical and instrumental management of male lower urinary tract symptoms. This is generally a long-term treatment strategy. Therefore, knowledge on the mid- to long-term placebo effect is of considerable interest. The paucity of data on this topic prompted us to investigate this issue in a meta-analysis. METHODS: All randomized controlled trials (RCTs) with the indication of benign prostatic hyperplasia and lower urinary tract symptoms containing a placebo- or sham treatment arm and with a follow-up of 12 months were eligible...
August 2017: Urology
https://www.readbyqxmd.com/read/28480542/the-effect-of-non-steroidal-anti-inflammatory-drugs-on-risk-of-benign-prostatic-hyperplasia
#13
Lotta H Nygård, Kirsi Talala, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen, Teemu J Murtola
BACKGROUND: Inflammation may play a role in pathogenesis of benign prostatic hyperplasia (BPH). However, the role of non-steroidal anti-inflammatory drugs (NSAIDs) as BPH risk factor is unclear. The objective of this study was to examine risk of BPH by NSAID use in a population-based cohort. METHODS: A total of 74 754 Finnish men without previous BPH at baseline in 1996-1999 were linked to national medication reimbursement database for information on physician-prescribed NSAID purchases during 1995-2009...
June 2017: Prostate
https://www.readbyqxmd.com/read/28455944/patterns-of-medical-management-of-overactive-bladder-oab-and-benign-prostatic-hyperplasia-bph-in-the-united-states
#14
Jennifer T Anger, Howard B Goldman, Xuemei Luo, Martin O Carlsson, Douglass Chapman, Kelly H Zou, David Russell, Fady Ntanios, Canan B Esinduy, J Quentin Clemens
AIMS: Overactive bladder (OAB) and benign prostatic hyperplasia (BPH) are highly prevalent conditions that place a large burden on the United States (US) health care system. We sought to analyze patterns of prescription medication usage for incident OAB in men and women, and for incident BPH in men using US health insurance claims data. MATERIALS AND METHODS: This study used Truven Health MarketScan® Commercial and Medicare Supplemental Research databases. The data were pooled from diverse points of care...
April 28, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28455657/-prostate-artery-embolization-pae-technique-and-results
#15
A Kovács
CLINICAL/METHODICAL ISSUE: In the treatment of the benign prostatic hyperplasia (BPH) medical and surgical therapies have been established. STANDARD RADIOLOGICAL METHODS: Prostate artery embolization (PAE) is an innovative endovascular technique that might close the gap between both these procedures. PERFORMANCE: The PAE procedure is safe and has a low incidence of side effects. The efficacy of PAE has been proven for medium sized and large sized glands as well as for intravesical protrusions...
April 28, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28431996/comparison-of-silodosin-monotherapy-vs-silodosin-with-tadalafil-add-on-therapy-in-patients-with-benign-prostatic-hyperplasia
#16
Takashi Yoshida, Hidefumi Kinoshita, Seiji Shimada, Makoto Taguchi, Tadashi Matsuda
OBJECTIVE: To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH) treated with the α1-adrenoceptor blocker silodosin. MATERIALS AND METHODS: We analyzed 103 patients with LUTS/BPH with an International Prostate Symptom Score (IPSS) of >8 after ≥4 weeks of silodosin treatment from April 2016 through December 2016 at Kori Hospital...
August 2017: Urology
https://www.readbyqxmd.com/read/28394524/-x-ray-guided-endovascular-surgery-in-patients-with-benign-prostatic-hyperplasia-and-prostate-cancer
#17
A I Neimark, M A Tachalov, B A Neimark, D V Torbik, D D Arzamastsev
AIM: To evaluate the efficacy and safety of superselective embolization and chemoembolization of the prostatic artery as an independent method of treating prostate cancer and BPH. MATERIALS AND METHODS: From 2004 to 2015, 116 patients with BPH (mean age 73.2+/-5.2 years) underwent prostatic artery embolization. Mean prostate volume ranged from 55 to 296 cc3. From 2011 to 2015, 37 patients with prostate cancer (mean age 72.3+/-2.06 years) were treated with X-ray-guided endovascular chemoembolization...
April 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28394492/treatment-patterns-and-patient-reported-outcomes-in-benign-prostatic-hyperplasia-patients-with-overactive-bladder-symptoms
#18
Yong Hyun Park, Tae Hyo Kim, Seung Wook Lee, Byung Ha Chung, Jin Seon Cho, Ji Youl Lee
OBJECTIVES: We aimed to examine the treatment patterns, and patient-reported outcomes (PROs) in benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. METHODS: Seven hundred and forty seven patients were included in this prospective observational study. The primary endpoint was to describe the medical treatment patterns for BPH patients with OAB symptoms. The secondary endpoint was to determine the PROs of these patients. Clinical outcome was assessed using International prostate symptom score (IPSS), and PROs were measured using BPH-Related QoL Questionnaire Korea 1 (BPH QoL K1) and Euroqol-5 Dimension (EQ-5D)...
May 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28319477/emerging-techniques-in-truly-minimal-invasive-treatment-options-of-benign-prostatic-obstruction
#19
Karl-Dietrich Sievert, Thomas Kunit
PURPOSE OF REVIEW: Benign prostatic enlargement is a common age-related condition, affecting over 50% of men aged more than 60 years. Side effects of medical therapy and significant morbidity of transurethral resection of the prostate and open surgery led to the development of so-called minimally invasive procedures, with the aim to be efficient but with less morbidity and shorter or no hospitalization. For this review, a systematic literature was performed. We report recent results in different treatment options for benign prostate hypoplasia (BPH) and recommend the best minimal-invasive treatment for BPH...
May 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28270016/urolift-minimally-invasive-surgical-bph-management
#20
REVIEW
Anish Pushkaran, Victoria Stainer, Gordon Muir, Iqbal S Shergill
An ideal treatment option for symptomatic Benign Prostatic Hyperplasia (BPH) should relieve lower urinary tract symptoms (LUTS) and restore Quality of Life (QoL). Currently available medical therapies and surgical options for symptomatic BPH have side effects that adversely affects quality of life. Prostatic urethral lift (PUL) is a novel endourology procedure that promises to relieve LUTS without the aforementioned side effects. Areas covered: We diligently reviewed all the published literature on PUL, till July 2016 using standard search criteria...
March 2017: Expert Review of Medical Devices
keyword
keyword
79263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"